Cancer occurrence during follow-up of the CAPP2 study -aspirin use for up to four years significantly reduces Lynch syndrome cancers for up to several years after completion of therapy

Benzer Materyaller

• Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial
  Yazar:: Burn, John, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
  Yazar:: Burn, John, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Prevalence of Adenomas and Hyperplastic Polyps in Mismatch Repair Mutation Carriers Among CAPP2 Participants: Report by the Colorectal Adenoma/Carcinoma Prevention Programme 2
  Yazar:: Liljegren, Annelie, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• The Risk of Extra-colonic, Extra-endometrial Cancer in the Lynch Syndrome
  Yazar:: Watson, Patrice, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database
  Yazar:: Møller, Pål, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)